Skip to main content

ABBOTT LABORATORIES

For the period ended Dec 31, 2024. Filed Feb 21, 2025.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Feb 21, 2025

ABT$110.51+0.5%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Consolidated Statement of Comprehensive Income

Year Ended December 31
202420232022
Net Earnings$13,402$5,723$6,933
Foreign currency translation gain (loss) adjustments(1,001)229(894)
Net actuarial gains (losses) and prior service cost and credits and amortization of net actuarial losses and prior service cost and credits, net of taxes of $228 in 2024, $31 in 2023 and $330 in 20227651171,177
Net gains (losses) on derivative instruments designated as cash flow hedges, net of taxes of $48 in 2024, $(66) in 2023 and $11 in 2022169(134)40
Other Comprehensive Income (Loss)(67)212323
Comprehensive Income$13,335$5,935$7,256
Supplemental Accumulated Other Comprehensive Income (Loss) Information, net of tax as of December 31:
Cumulative foreign currency translation (loss) adjustments$(7,505)$(6,504)$(6,733)
Net actuarial (losses) and prior service (cost) and credits(611)(1,376)(1,493)
Cumulative gains (losses) on derivative instruments designated as cash flow hedges21041175
Accumulated other comprehensive income (loss)$(7,906)$(7,839)$(8,051)
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.